Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers - Schluep, Thomas; Lickliter, Jason; Hamilton, James; Lewis, David L.; Lai, Ching‐Lung; Lau, Johnson YN; Locarnini, Stephen A.; Gish, Robert G.; Given, Bruce D. (Clinical pharmacology in drug development, 2017)
Keywords: Adult; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - pharmacokinetics; Cytokines; Double-Blind Method; Female; Half-Life; Healthy Volunteers; Hepatitis; Hepatitis B; Hepatitis B, Chronic - drug therapy; Histamine; Histamine Antagonists - administration & dosage; Humans; Infusions, Intravenous; Male; Middle Aged; Original; Pharmacokinetics; Pharmacology; phase 1; Pre-Exposure Prophylaxis - methods; RNA Interference; RNAi; safety; tolerability; treatment; viral hepatitis; volunteers; Young Adult; treatment; viral hepatitis; RNAi; phase 1; RNA interference; hepatitis B; safety; pharmacology; tolerability; pharmacokinetics; volunteers